Soumettre la recherche
Mettre en ligne
A Peek at GCT 2012
•
1 j'aime
•
925 vues
C
ConferenceForum
Suivre
3rd Annual Executing Global Clinical Trials, Sept 2012, Mitchell Katz, Purdue Pharma L.P.
Lire moins
Lire la suite
Business
Signaler
Partager
Signaler
Partager
1 sur 40
Télécharger maintenant
Télécharger pour lire hors ligne
Recommandé
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
Dismantling Barriers to Adaptive Design Adoption to Be Key Theme of Pre-Disru...
ConferenceForum
Steve Hoffmann
Steve Hoffmann
ConferenceForum
A Peek at CMO East 2013
A Peek at CMO East 2013
ConferenceForum
A Peek at Dpharm 2012
A Peek at Dpharm 2012
ConferenceForum
A Peek at CMO East 2013
A Peek at CMO East 2013
ConferenceForum
A Peek at GCT 2012 - Eileen Daniels
A Peek at GCT 2012 - Eileen Daniels
ConferenceForum
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Statistical Thinking and Pharmaceutical Professional Development, a keynote b...
Ajaz Hussain
Online Resources to Support Open Drug Discovery Systems
Online Resources to Support Open Drug Discovery Systems
US Environmental Protection Agency (EPA), Center for Computational Toxicology and Exposure
Contenu connexe
Similaire à A Peek at GCT 2012
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
eugeniadean34240
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
Ankur Khanna
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare Design
Richard Hogue
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416
Chirag Patel
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Sean Ekins
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discovery
pharmaindexing
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
Stockholm Institute of Transition Economics
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call tool
Christine Wekerle
Searching for Relevant Studies
Searching for Relevant Studies
Effective Health Care Program
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
healdkathaleen
New Product Planning and Medical Affairs
New Product Planning and Medical Affairs
Anthony Russell
Implicate order Probabilistic Semantics
Implicate order Probabilistic Semantics
Srinidhi Boray
The Drug Development Process Kerentech
The Drug Development Process Kerentech
EstherMM
When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...
US Environmental Protection Agency (EPA), Center for Computational Toxicology and Exposure
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
Joanne Sienko Ott, CFA, MA
apcp Deeksha Bhartiya
apcp Deeksha Bhartiya
Ravi Mehrotra MD,PhD, FRCPath, FAMS
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
SUBHI7
Literature Review on Health & Safety
Literature Review on Health & Safety
HR at VASHI ELECTRICALS PVT. LTD.
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Final
kdjamies
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Jean-Claude Bradley
Similaire à A Peek at GCT 2012
(20)
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
2. This exercise uses the dataset WholeFoods.” (a) Use Excel to.docx
Data Mining and Big Data Analytics in Pharma
Data Mining and Big Data Analytics in Pharma
A Review Of The Research Literature On Evidence-Based Healthcare Design
A Review Of The Research Literature On Evidence-Based Healthcare Design
Bioinformatics Strategies for Exposome 100416
Bioinformatics Strategies for Exposome 100416
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Collaborative Drug Discovery: A Platform For Transforming Neglected Disease R...
Translational pharmacology new approach of drug discovery
Translational pharmacology new approach of drug discovery
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
There’s No Escape from External Validity – Reporting Habits of Randomized Con...
Knowledge Translation in Child Welfare: Researcher-on-call tool
Knowledge Translation in Child Welfare: Researcher-on-call tool
Searching for Relevant Studies
Searching for Relevant Studies
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
Running head HEALTH PROMOTION IN MINORITY POPULATIONS .docx
New Product Planning and Medical Affairs
New Product Planning and Medical Affairs
Implicate order Probabilistic Semantics
Implicate order Probabilistic Semantics
The Drug Development Process Kerentech
The Drug Development Process Kerentech
When pharmaceutical companies publish large datasets an abundance of riches o...
When pharmaceutical companies publish large datasets an abundance of riches o...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
A Value Proposition for Creating Crowdfunding Research Platform for Integrati...
apcp Deeksha Bhartiya
apcp Deeksha Bhartiya
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Roddy Analysis WorksheetUsing the worksheet below, complete an.docx
Literature Review on Health & Safety
Literature Review on Health & Safety
Knowledge Discovery And Data Mining Of Free Text Final
Knowledge Discovery And Data Mining Of Free Text Final
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Mel Reichman on Pool Shark’s Cues for More Efficient Drug Discovery
Plus de ConferenceForum
A Peek at Dpharm 2012
A Peek at Dpharm 2012
ConferenceForum
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
ConferenceForum
Scott Harris
Scott Harris
ConferenceForum
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
ConferenceForum
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging Markets
ConferenceForum
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
ConferenceForum
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz Stoner
ConferenceForum
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012
ConferenceForum
Ian sanderson
Ian sanderson
ConferenceForum
Ian sanderson
Ian sanderson
ConferenceForum
Ian sanderson
Ian sanderson
ConferenceForum
Podd slides 1
Podd slides 1
ConferenceForum
Podd slides
Podd slides
ConferenceForum
Podd slide deck mark kontny
Podd slide deck mark kontny
ConferenceForum
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1
ConferenceForum
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012
ConferenceForum
Sohini Chowdhury, 2011
Sohini Chowdhury, 2011
ConferenceForum
Plus de ConferenceForum
(17)
A Peek at Dpharm 2012
A Peek at Dpharm 2012
Strategies for Developing & Commercializing Biobetters & Biosimilars
Strategies for Developing & Commercializing Biobetters & Biosimilars
Scott Harris
Scott Harris
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
Thomas Krohn - Dpharm 2012 - Disruptive Innovation: Moving Beyond the Talk
GCT 2012 Helmut Wolf Keynote on Emerging Markets
GCT 2012 Helmut Wolf Keynote on Emerging Markets
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Dpharm 2012: Using Innovative Partnerships to Drive Measurable Progress in Gl...
Changing Paradigms in Outsourcing, Liz Stoner
Changing Paradigms in Outsourcing, Liz Stoner
Kent Rogers, Acorda, New Paradigms 2012
Kent Rogers, Acorda, New Paradigms 2012
Ian sanderson
Ian sanderson
Ian sanderson
Ian sanderson
Ian sanderson
Ian sanderson
Podd slides 1
Podd slides 1
Podd slides
Podd slides
Podd slide deck mark kontny
Podd slide deck mark kontny
Podd c no.1366 salles final oct 2011-1
Podd c no.1366 salles final oct 2011-1
Matt Whalen & Linda Strause GCT 2012
Matt Whalen & Linda Strause GCT 2012
Sohini Chowdhury, 2011
Sohini Chowdhury, 2011
Dernier
How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K Subscribers
Flyyx Tech
14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdf
Eni
Benihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdf
javenxxx01
Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 Update
Adnet Communications
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Business
tompeter3736
Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..
ranjithapriya2
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
Louis Malaybalay
Record of Module Forensic photography in
Record of Module Forensic photography in
alexademileighpacal
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
ShainaMaheshwari1
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
believeminhh
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdf
meftaul987
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egypt
opstechsanjanasingh
WAM Corporate Presentation Mar 12 2024_Video.pdf
WAM Corporate Presentation Mar 12 2024_Video.pdf
Western Alaska Minerals Corp.
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
endeworku
EPC Contractors aspects Presentation.pdf
EPC Contractors aspects Presentation.pdf
Giuseppe Tommasone
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
PaulBryant58
Digital Marketing Training Program skills s
Digital Marketing Training Program skills s
godxzyrox
Wallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loan
sujat8807
HOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETING
NATHAN SPEAKS
unfinished legacy it is a clothing brand
unfinished legacy it is a clothing brand
akashm530190
Dernier
(20)
How The Hustle Milestone Referral Program Got 300K Subscribers
How The Hustle Milestone Referral Program Got 300K Subscribers
14 march 2024-capital-markets-update eni.pdf
14 march 2024-capital-markets-update eni.pdf
Benihana of Tokyo case study11111111.pdf
Benihana of Tokyo case study11111111.pdf
Strategic Resources Corporate Presentation - March 2024 Update
Strategic Resources Corporate Presentation - March 2024 Update
Unleashing the Power of Fandom: A Short Guide to Fan Business
Unleashing the Power of Fandom: A Short Guide to Fan Business
Shravan Kumaran and sanjay kumaran.pdf..
Shravan Kumaran and sanjay kumaran.pdf..
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
3BBE: THE FUTURE OF ECOMMERCE PRESENTATION - LOUIS MALAYBALAY
Record of Module Forensic photography in
Record of Module Forensic photography in
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
A Comprehensive Case Study on the IL&FS Crisis (final).pptx
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
The Vietnam Believer_Newsletter_Vol.001_Mar12 2024
A Case Study On SQUARE GROUP Bangladesh.pdf
A Case Study On SQUARE GROUP Bangladesh.pdf
Mist Cooling & Fogging System Company in Egypt
Mist Cooling & Fogging System Company in Egypt
WAM Corporate Presentation Mar 12 2024_Video.pdf
WAM Corporate Presentation Mar 12 2024_Video.pdf
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
Bus Eth ch3 ppt.ppt business ethics and corporate social responsibilities ppt
EPC Contractors aspects Presentation.pdf
EPC Contractors aspects Presentation.pdf
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Streamlining Your Accounting A Guide to QuickBooks Migration Tools.pptx
Digital Marketing Training Program skills s
Digital Marketing Training Program skills s
Wallet Pitch for startup fintech and loan
Wallet Pitch for startup fintech and loan
HOW TO START EARNING WITH AFFILIATE MARKETING
HOW TO START EARNING WITH AFFILIATE MARKETING
unfinished legacy it is a clothing brand
unfinished legacy it is a clothing brand
A Peek at GCT 2012
1.
3rd$Annual$Execu.ve$Global$ Clinical$Trials$ Mitchell(Katz,(Ph.D.( Execu3ve(Director,(Medical(Research(Opera3ons( Purdue(Pharma(L.P.( September(2012(
2.
2( Pharma’s$Largest$Layoffs$in$2012$
3.
3( CRO$Consolida.on$ ! INC( " Kendle( !
Theorem( " Omnicare( " IBAH( ! Pharmanet/i3( " Inven3ve(Health( ! Private(Equity( " PPD( " RPS( " PRA(
4.
4( Outsourcing$Buzz$Words$ ! Partnerships( ! Alliances( !
Preferred(Models( ! Hybrid(Models( ! Func3onal(Models( ! Transac3onal(Models( ! Offshoring( ! “Strategic(Rela3onships”(
5.
5( Johnson$&$Johnson$and$ICON$ #1(–(Failure(to(ensure(proper(monitoring(of(the(clinical( inves3ga3ons([21(CFR(312.50(and(312.56(a)( #2(–(Failure(to(ensure(that(an(inves3ga3on(was(conducted(in( accordance(with(the(general(inves.ga.onal$plan$and( protocols(as(specified(in(the(IND([21(CFR(312.50]( #3(–(Failure(to(secure(inves.gator$compliance$with(the( inves3ga3onal(plan(and(applicable(FDA(regula3ons([21(CFR( 312.56(b)]( #4(–(Failure(to(ensure(that(only(inves3gators(who(were( qualified(by(training(and(experience(were(selected(as( appropriate(experts(to(inves3gate(a(drug([21(CFR(212.53(a)](
6.
6(
7.
7( It’s$All$About$.$.$.$ ( ( QUALITY$
8.
8( Avoca$Quality$Consor.um$ ( Pharma(and(Biotech(members((to(date):( ! Alexion(Pharmaceu3cals,(Amgen,(Astellas(Pharma,(AstraZeneca,(Biogen( Idec,(BristoldMyers(Squibb,(Cerexa,(Cubist(Pharmaceu3cals,(Daiichi( Sankyo,(Eli(Lilly(and(Company,(GlaxoSmithKline,(Grünenthal,(ImClone( Systems,(Janssen(Research(&(Development,(Otsuka,(Pfizer,(Purdue,(and( Roche( CRO(members((to(date):( ! Chiltern(Interna3onal,(Covance,(INC(Research,(ICON,(Harrison(Clinical( Research,(PAREXEL(Interna3onal,(PharmaNet/i3,(PRA(Interna3onal,( Quin3les,(Theorem(Clinical(Research,(and(RPS( ( Corporate(Sponsors:(
9.
Quality$Management$and$CRO$ Oversight$
10.
10( Agenda$ ! Overview:(Background(and(context( ! Part$1:(Overall(percep3ons(and(the( “disconnects”(between(sponsors(and(CROs( around(issues(of(quality( !
Part$2:(Root(causes(of(quality(issues(and(the( issue(of(“micromanagement”( ! Part$3:(Best(prac3ce(approaches(associated( with(sa3sfac3on( ! Open(discussion(
11.
11( Context$for$Research$on$Quality$and$ CRO$Oversight$ ! Increase(in(clinical(outsourcing( ! Consolida3on(of(spend(with(few(clinical(service(providers( !
Globaliza3on(of(clinical(trials:(increase(in(number(of(studies(in(lessdexperienced(developing( regions( ! Focus(on(efficiencies(and(cost(savings( ! Increase(in(the(number(of(highdprofile(FDA(warning(lemers( Focus(on(Avoca’s(2011(Industry(Survey:(percep3ons(from(sponsors(and(CROs(on(the(quality(of( outsourced(trials( Focus(of(Avoca’s(Quality(Consor3um:(proac3ve(quality(management( The$focus$and$vision$of$the$Quality$Consor5um$are$to$accelerate$the$development$of$an$industry$ standard$and$best9prac5ce$approach$to$the$quality$management$of$outsourced$trials$through$the$ sharing$of$best$prac5ces$
12.
12( Methods$ ! Surveys(explored(respondents’(views(and(experiences(regarding:( " Sa3sfac3on(with(quality(of(work(delivered(by(clinical(service(providers( "
Approaches(to(managing(quality(in(outsourced(clinical(trials,(including( quality(metrics,(repor3ng(tools,(and(desktop(analy3cs( " Scope(and(u3lity(of(Quality(Agreements( " Other(tools(used(to(set(expecta3ons(for(quality(in(outsourced(clinical( trials( " Quality(concerns(and(management(when(outsourcing(in(Emerging( Markets( " Quality(considera3ons(in(selec3ng(CROs(
13.
13( 2011$Industry$Survey$ ! 104(sponsor(surveys(from(66( companies( " 73%(pharma,( 17%(biotech( "
52%(“Top(20”( " 44%(Opera3ons,( 40%(Outsourcing( " 17%(execu3ves,( 58%(middle(management(( ! 143(provider(surveys(from(88( companies( " 78%(CROs( " 64%(“Top(20”( " 38%(Opera3ons,( 31%(BD,( 22%(Management( " 48%(execu3ves,( 39%(middle(management(( 247(Surveys(
14.
14( Quality$Consor.um$Assessment$ ! 428(sponsor(surveys(were(deployed(resul3ng(in(feedback(from(334( individuals( " Overall(response(rate:(78%( "
Completed(surveys/company:(10d46((note(that(there(was(no(associa3on( between(company(size(and(number(of(respondents)( " Range(of(response(rates/company:(50%d100%( ! 298(CRO(surveys(were(deployed(resul3ng(in(feedback(from(207(individuals( " Overall(response(rate:(69%( " Completed(surveys/company:(4d59((note(that(there(was(no(associa3on( between(company(size(and(number(of(respondents)( " Range(of(response(rates/company:(27%d100%(
15.
Part$1:$$Framing$the$Quality$Issue$ Overall(percep3ons(and(the( “disconnects”(between(sponsors(and( CROs(around(issues(of(quality(
16.
16( Methods$ ! “Quality”(was(defined(as(“The$ability$to$effec.vely$and$efficiently$answer$ the$intended$ques.on$about$the$benefits$and$risks$of$a$medical$product$ or$procedure$while$assuring$pa.ent$safety$and$protec.on$of$human$ subjects”$ ! As(examples,(elements(of(a(quality(clinical(study(were(said(to(include,(but( not(limited(to:( "
Scien3fically(valid(and(ethically(sound(experimental(design( " Adequate(protec3on(of(subjects’(rights,(safety(and(welfare( " Qualified(personnel( " Adequate(monitoring( " Current,(complete,(and(accurate(data( " Accurate(presenta3on(and(interpreta3on(of(data(
17.
17( Industry$Survey$Sponsors:$Overall$ Sa.sfac.on$
18.
18( Consor.um$Sponsors:$Sa.sfac.on$ with$Quality$
19.
19( Consor.um$Sponsors:$Comparison$of$ CRO$Quality$to$Sponsor$Internal$ Teams$
20.
20( Sa.sfac.on$with$Quality$
21.
21( Industry$Survey:$Provider$Sa.sfac.on$
22.
22( Sponsors:$Sa.sfac.on$with$Quality$ Areas(with(rela3vely(high(sa3sfac3on(included:( ! Compliance(with(SOPs(and(other(wrimen(procedures( ! Data$quality$and$integrity$ !
Audit(plans(and(execu3on( Areas(with(rela3vely(high(dissa3sfac3on(included:( ! Oversight(of(third(party(vendors( ! Governance(of(quality( ! Communica3ons(surrounding(quality( ! Availability(of(quality(personnel(for(projects( ! Efficiency/.meliness$in$achieving$clean$data$ ! Adherence(to(monitoring(plan(
23.
Part$2:$$Causes$of$Quality$Issues$
24.
24( Causes$of$Issues$with$Quality$ “CROs,$as$service$providers,$are$heavily$incented$to$ deliver$and$measure$quality$–$and$are$prepared$to$do$ so.$$Too$many$sponsors$are$not$prepared$to$do$their$ part$in$assuring$a$rela5onship$focused$on$quality.$$So$ CROs$are$forced$to$implement$one$model$for$sponsors$ ready$to$focus$on$quality,$and$another$for$the$many$ focused$on$ac5vi5es$and$unit9level$cost.”$ ( ( (d(Quota3on(from(an(Industry(Survey(Provider(Respondent( ( (
25.
25( Causes$of$Issues$with$Quality:$Sponsor$ Consor.um$Data$
26.
26( Industry$Survey:$Causes$of$Issues$with$ Quality$
27.
27( Quality$vs.$Costs$
28.
28( Causes$of$Issues$with$Quality$ #1:$Cost$Pressures$ “The$focus$on$price$has$driven$out$the$reality$of$adequate$ monitoring$and$proper$Quality$Control$processes$to$ensure$quality$ at$the$site$level…$Too$many$procurement$officers$are$making$ decisions$purely$on$cost$without$regards$to$quality$product.”$ “Price$pressures,$especially$discounts…have$caused$some$CROs$to$ cut$corners$and$send$work$to$low$cost$regions$without$adequately$ trained$staff.”$ “Price$reduc5ons$required$to$‘play$the$game’$in$the$preferred$ provider$selec5on$process$make$it$very$difficult$to$con5nue$to$ resource$adequately.$$Sponsors$say$they$will$streamline$processes$ going$forward$to$reduce$workload$but$hardly$ever$do.”$
29.
29( Causes$of$Issues$with$Quality$ #2:(Sponsors(DecisiondMaking(with( Impacts(on(Quality((without(provider( input)( ! Oversight((level(of(monitoring)( ! Protocol(design( !
Inves3gators(&(regions( ! Timelines( ! Processes( ! Thirddparty(vendors( “It$is$difficult$to$ensure$quality$for$a$func5onal$provider$for$monitoring,$when$ the$protocol$design/site$selec5on$are$done$by$another$CRO/sponsor.”$ “There$is$a$percentage$of$work$that$we$perform$that$is$working$with$the$ sponsor$processes,$etc…in$these$circumstances,$quality,$5meliness,$training,$ governance$and$oversight$are$dictated$by$sponsor$requirements.”$
30.
30( Causes$of$Issues$with$Quality$ #3:$Sponsor$Failure$to$Proac.vely$Make$Decisions$or$ Communicate$with$Providers$about$Quality$Expecta.ons$ Industry(survey(data:( ! Only(55%(of(sponsors(are(sa3sfied(with(their(companies’(iden3fica3on(of(process/ deliverables(for(which(quality(expecta3ons(of(CROs(need(to(be(set.( ! Only(58%(feel(that(their(companies(effec3vely(communicate(quality(expecta3ons( to(CROs( !
Strong(associa3on(between(“proac3ve”(management(of(quality(and(ability(to( forego(micromanagement.(
31.
Part$3:$$Results$ What(can(be(done(to(enhance(quality(while( reducing(micromanagement?( What$quality$prac.ces$are$associated$with$ enhanced$sa.sfac.on?$
32.
32( Industry$Survey$Sponsors:$Quality$ Metrics$
33.
33( Consor.um$Survey:$Quality$Metrics$
34.
34( Quality$Agreements$
35.
35( Industry$Survey$Sponsors:$Quality$ Agreements$
36.
36( Industry$Survey$Sponsors:$Quality$ Agreements$
37.
37( Other$Prac.ces$Impac.ng$Quality$ Risk$Based$Approaches$ ! 57%(of(sponsors(and(58%(of(CROs(use(a(formal,(riskdbased( approach(to(levels(of(site(monitoring((industry(survey(data)( " About(2/3(have(had(primarily(posi3ve(experiences(–(1/3(mixed( !
Most(sponsors((67%)(and(CROs((79%)(do(maintain( documenta3on(of(site(performance(on(previous(trials(to( factors(into(such(models.( " Performance(data(most(commonly(includes(number(of(protocol( viola3ons,(number(of(queries,(type(and(severity(of(protocol( viola3ons,(promptness(of(data(entry,(types(of(queries,(and(3me( to(resolu3on(of(queries.(
38.
38( Quality$by$Region$
39.
39( Summary$ ! While(developing(standards(and(more( efficient(ways(for(sponsors(and(CROs(to(work( together(is(necessary,(it(has(been( challenging.( ! There(is(greater(poten3al(for(success(in( terms(of(the(ability(to(quickly(move(towards( standards:( (
( (Quality(Agreements( ( ( (Quality(Metrics( ! There(is(no(onedsize(fits(all(CRO(model(
40.
Open$Discussion$ ( Thank(You(
Télécharger maintenant